Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy

Stephen J. Greene, Stephen E. Epstein, Raymond J. Kim, Arshed A. Quyyumi, Robert T. Cole, Allen S. Anderson, Jane E. Wilcox, Hal A. Skopicki, Sergey Sikora, Lev Verkh, Nikolai I. Tankovich, Mihai Gheorghiade, Javed Butler

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Aims This article describes an ongoing study investigating the safety and efficacy of ischemia-tolerant mesenchymal stem cell (MSC) therapy in patients with nonischemic heart failure and dysfunctional viable myocardium without scarring. This study will follow principles of the previously described mechanistic translational-phase concept whereby the effect of the study agent on laboratory and imaging markers of cardiac structure and function will be tested in a small homogenous cohort with the goal to enhance the understanding of the effect of interventions on cardiac remodeling and performance. Study design This single-blind, placebo-controlled, crossover, multicenter, randomized study will assess the safety, tolerability, and preliminary efficacy of a single intravenous (i.v.) dose of allogeneic ischemia-tolerant MSCs in individuals with heart failure of nonischemic cause, ejection fraction 40% or less, and dysfunctional viable myocardium who have been receiving guideline-directed medical therapy. Eligible patients will have no evidence of baseline replacement scarring on delayed-enhancement cardiac magnetic resonance (CMR). Approximately 20 patients will be randomized in a 1: 1 ratio to receive an i.v. infusion of ischemia-tolerant MSCs or placebo. At 90 days, the two groups will undergo crossover and received the alternative treatment. The primary endpoint is safety, as evaluated through at least 1-year post-MSC infusion. Additional efficacy endpoints will include measures of cardiac structure and function, as evaluated by serial cine-CMR and transthoracic echocardiography at 90 and 180 days post-initial infusion. Conclusion This pilot study will explore the safety and effects on cardiac structure and function of i.v. injection of ischemia-tolerant MSCs in a small homogenous cohort of nonischemic heart failure patients with reduced ejection fraction and absent replacement scarring on CMR. This study also represents a prospective mechanistic translational-phase study using baseline and serial CMR imaging in heart failure patients and serves as a potential model for design of future heart failure trials (ClinicalTrials.gov identifier: NCT02467387).

Original languageEnglish (US)
Pages (from-to)283-290
Number of pages8
JournalJournal of Cardiovascular Medicine
Volume18
Issue number4
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • Clinical trial
  • Heart failure
  • Nonischemic
  • Stem cells
  • Viable myocardium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy'. Together they form a unique fingerprint.

  • Cite this

    Greene, S. J., Epstein, S. E., Kim, R. J., Quyyumi, A. A., Cole, R. T., Anderson, A. S., Wilcox, J. E., Skopicki, H. A., Sikora, S., Verkh, L., Tankovich, N. I., Gheorghiade, M., & Butler, J. (2017). Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. Journal of Cardiovascular Medicine, 18(4), 283-290. https://doi.org/10.2459/JCM.0000000000000303